Prothena Corporation plc

NasdaqGS PRTA

Prothena Corporation plc Return on Assets (ROA) for the year ending December 31, 2023: -21.11%

Prothena Corporation plc Return on Assets (ROA) is -21.11% for the year ending December 31, 2023, a -36.85% change year over year. Return on assets measures profitability against assets; higher ROA indicates efficient asset use and profitability.

Prothena Corporation plc Return on Assets (ROA) for the year ending December 31, 2022 was -15.43%, a -240.37% change year over year.
Prothena Corporation plc Return on Assets (ROA) for the year ending December 31, 2021 was 10.99%, a 132.93% change year over year.
Prothena Corporation plc Return on Assets (ROA) for the year ending December 31, 2020 was -33.38%, a -80.17% change year over year.
Prothena Corporation plc Return on Assets (ROA) for the year ending December 31, 2019 was -18.53%, a 40.63% change year over year.

Key data

Date	Return on Assets (ROA)	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio

NasdaqGS: PRTA

Prothena Corporation plc

CEO	Dr. Gene G. Kinney Ph.D.
IPO Date	Dec. 18, 2012
Location	Ireland
Headquarters	77 Sir John Rogerson’s Quay
Employees	173
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.

Key trends

Past 5 years